阿托伐他汀在老年冠心病患者一级和二级预防中的有效性和安全性研究进展  

Research progress on the effectiveness and safety of atorvastatin in primary and secondary prevention of elderly coronary heart disease patients

作　　者：郑美华 郑彬彬[1] Zheng Meihua;Zheng Binbin(Department of Cardiovascular,Tianjin Beichen Hospital,Tianjin 300400,China)

机构地区：[1]天津市北辰医院,天津300400

出　　处：《首都食品与医药》2023年第16期18-21,共4页Capital Food Medicine

基　　金：天津市北辰医院院级科研项目(编号:SHGY-2021017SHGY-2020034)。

摘　　要：如今,老年人患冠心病(CHD)的风险增加,并且因CHD而导致老年人死亡的风险持续升高。多项临床试验评估了他汀类药物对患有冠心病或有患冠心病风险的人群的有益作用。这些试验提供的证据表明,即使在老年患者中,他汀类药物也能降低老年冠心病患者死亡风险并改善临床结果。其中阿托伐他汀已在老年受试者中进行了广泛研究,对CHD患者具有显著疗效。阿托伐他汀的药代动力学特性使其可以每隔一天服用一次,这一因素可以减少不良事件的发生,对老年人尤为重要。此文通过对近几年有关阿托伐他汀在老年冠心病患者一级和二级预防中的安全性和有效性进行分析,为阿托伐他汀在老年冠心病患者的进一步应用提供参考。Now,the risk of coronary heart disease(CHD)in the elderly increases,and the risk of death in the elderly population continues to increase due to the proportion of CHD.Multiple clinical trials have evaluated the beneficial effects of statins on populations with or at risk of coronary heart disease.These trials provide evidence that even in elderly patients,statins are It can reduce the risk of death in elderly patients with coronary heart disease and improve clinical outcomes.Among them,atorvastatin has been extensively studied in elderly subjects and has significant therapeutic effects on CHD patients.The pharmacokinetic properties of atorvastatin allow it to be taken every other day,which can reduce the incidence of adverse events and is particularly important for elderly people.This article provides reference for the further application of atorvastatin in elderly patients with coronary heart disease by examining the safety and effectiveness of atorvastatin in primary and secondary prevention in elderly patients with coronary heart disease in recent years.

关 键 词：阿托伐他汀 他汀类药物 HMG-COA还原酶抑制剂 冠心病 老年患者 

分 类 号：R541.4[医药卫生—心血管疾病]